Abvd | List of Frontiers open access articles

Review

Published on 16 Nov 2021

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

in Pharmacology of Anti-Cancer Drugs

Fajun Pei
Yang Yu
Bin Dong
Hui Guan
Xinzhe Dong
Fen Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2021.694545

5,084 views
6 citations

Original Research

Published on 21 Apr 2023

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease

in Hematologic Malignancies

Mariavita Ciccarone
Paola Cavaceppi
Cristiano Tesei
Stefania Brunetti
Alessandro Pulsoni
Ombretta Annibali
Cristiano Gasparoli
Roberta Battistini
Stefan Hohaus
Sabrina Pelliccia

Frontiers in Oncology

doi 10.3389/fonc.2023.1059393

5,304 views
7 citations

Review

Published on 18 Apr 2024

Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

in Hematologic Malignancies

Charles J. Milrod
Ari Pelcovits
Thomas A. Ollila

Frontiers in Oncology

doi 10.3389/fonc.2024.1397053

3,911 views
6 citations

Case Report

Published on 10 Aug 2017

Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report

in Multiple Sclerosis and Neuroimmunology

Linda Borellini
Silvia Lanfranconi
Sara Bonato
Ilaria Trezzi
Giulia Franco
Lorella Torretta
Nereo Bresolin
Alessio Barnaba Di Fonzo

Frontiers in Neurology

doi 10.3389/fneur.2017.00401

21,822 views
26 citations

Original Research

Published on 05 Sep 2024

Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

in Hematologic Malignancies

Alessandro Cellini
Chiara Adele Cavarretta
Francesco Angotzi
Valeria Ruocco
Andrea Serafin
Nicolò Danesin
Marco Pizzi
Michele Gregianin
Stefania Vio
Filippo Crimì

Frontiers in Oncology

doi 10.3389/fonc.2024.1419118

2,238 views

Case Report

Published on 14 Jan 2022

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report

in Cancer Immunity and Immunotherapy

Chunting Zhu
Yi Zhao
Fang Yu
Weijia Huang
Wenjun Wu
Jingsong He
Zhen Cai
Donghua He

Frontiers in Immunology

doi 10.3389/fimmu.2021.756583

11,007 views
10 citations

Original Research

Published on 03 Sep 2025

Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China

in Viral Immunology

Xiping Liang
Chaoyu Wang
Yifeng Tang
Xiaoqing Xie
Yan Wu
Haiyan Min
Wei Zhang
Wenwen Zhou
Vishnu Prasad Adhikari
Xiaomei Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2025.1628909

2,202 views

Original Research

Published on 25 Oct 2024

Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low–middle-income country

in Pediatric Oncology

Youssef Madney
Amr Abdalla
Soha Ahmed
Marwa Romeih
Sally Fikry
Engy Mohammed
Hala Taha
Mohamed Zaghloul
Eman Attia

Frontiers in Oncology

doi 10.3389/fonc.2024.1432650

2,771 views
3 citations

Original Research

Published on 27 Jun 2023

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma

in Pediatric Oncology

Ahmed Mahdy
Asmaa Hamoda
Ahmed Zaher
Eman Khorshed
Madeha Elwakeel
Omneya Hassanein
Iman Sidhom

Frontiers in Oncology

doi 10.3389/fonc.2023.1153128

3,892 views
6 citations

Original Research

Published on 11 Feb 2022

Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India

in Hematologic Malignancies

Dinesh Bhurani
Reena Nair
Senthil Rajappa
Suparna Ajit Rao
Nithya Sridharan
Rakesh Reddy Boya
Ganapathi S. Raman
Hari Menon
Arun Seshachalam
Ramesh Nimmagadda

Frontiers in Oncology

doi 10.3389/fonc.2021.799948

8,417 views
20 citations

Original Research

Published on 20 Oct 2022

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD

in Molecular and Cellular Oncology

Antonio Santisteban-Espejo
Irene Bernal-Florindo
Jose Perez-Requena
Lidia Atienza-Cuevas
Nieves Maira-Gonzalez
Marcial Garcia-Rojo

Frontiers in Oncology

doi 10.3389/fonc.2022.1000762

3,887 views
7 citations

Articles

Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma

Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin’s disease

Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects

Progressive Encephalomyelitis with Rigidity and Myoclonus Associated With Anti-GlyR Antibodies and Hodgkin’s Lymphoma: A Case Report

Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD

Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report

Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China

Exploring the complexity, treatment challenges, and outcomes in pediatric nodular lymphocyte predominant Hodgkin lymphoma: a perspective from a low–middle-income country

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma

Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India

Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD